Verve Therapeutics, Inc. (VERV): Price and Financial Metrics
GET POWR RATINGS... FREE!
VERV Stock Price Chart Interactive Chart >
VERV Price/Volume Stats
|Current price||$36.34||52-week high||$56.18|
|Prev. close||$36.15||52-week low||$10.70|
|Day high||$37.43||Avg. volume||876,172|
|50-day MA||$34.65||Dividend yield||N/A|
|200-day MA||$26.12||Market Cap||2.19B|
Verve Therapeutics, Inc. (VERV) Company Bio
Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.
Most Popular Stories View All
VERV Latest News Stream
|Loading, please wait...|
VERV Latest Social Stream
View Full VERV Social Stream
Latest VERV News From Around the Web
Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.
There's a new Ark fund in town, and its name is the ARK Venture Fund.
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL.
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences: Guggenheim 2022 Nantucket Therapeutics Conference (fireside chat) on Wednesday, September 28, 2022, at 7:30 a.m. ET in Nantucket, Mass.;Jefferies Cell and Genetic Medicine Summit 2022
The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style.
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for VERVE-101 as a potential treatment for patients with heterozygous familial hypercholesterolemia (He
VERV Price Returns